Corcept Therapeutics
CORT
₹5,939
Share price
-1.37%
Change (1 day)
94.14%
Change (1 year)
Categories
Corcept Therapeutics (CORT) - Cash on Hand
Cash on Hand as of March 2025 : ₹28.10 Billion
According to Corcept Therapeutics
's latest financial reports the company has ₹28.10 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Corcept Therapeutics - Cash on Hand chart (from 2003 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | ₹32.88 B | 7.28% |
| 2023-12-31 | ₹30.65 B | -14.18% |
| 2022-12-31 | ₹35.72 B | 114.69% |
| 2021-12-31 | ₹16.63 B | -48.38% |
| 2020-12-31 | ₹32.22 B | 63.78% |
| 2019-12-31 | ₹19.67 B | 36.12% |
| 2018-12-31 | ₹14.45 B | 155.14% |
| 2017-12-31 | ₹5.66 B | 61.8% |
| 2016-12-31 | ₹3.50 B | 30.33% |
| 2015-12-31 | ₹2.68 B | 74.85% |
| 2014-12-31 | ₹1.53 B | -54.67% |
| 2013-12-31 | ₹3.39 B | -33.44% |
| 2012-12-31 | ₹5.09 B | 142.94% |
| 2011-12-31 | ₹2.09 B | 90.38% |
| 2010-12-31 | ₹1.10 B | -0.55% |
| 2009-12-31 | ₹1.10 B | 25.84% |
| 2008-12-31 | ₹0.88 B | 29.12% |
| 2007-12-31 | ₹0.68 B | 62.73% |
| 2006-12-31 | ₹0.41 B | -68% |
| 2005-12-31 | ₹1.30 B | -19.21% |
| 2004-12-31 | ₹1.61 B | 207.29% |
| 2003-12-31 | ₹0.52 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | ₹3.377 T | 11,915.32% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹1.025 T | 3,550.36% | 🇺🇸 USA |
 Novartis NVS | ₹626.62 B | 2,129.50% | 🇨🇭 Switzerland |
 Eli Lilly LLY | ₹280.45 B | 897.85% | 🇺🇸 USA |
 Pfizer PFE | ₹1.507 T | 5,264.93% | 🇺🇸 USA |
 Merck MRK | ₹803.57 B | 2,759.06% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | ₹9.98 B | -64.48% | 🇺🇸 USA |
 MannKind Corp MNKD | ₹15.80 B | -43.75% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | ₹110.79 B | 294.20% | 🇺🇸 USA |